NGM Biopharma 
Welcome,         Profile    Billing    Logout  
 9 Products   0 Diseases   9 Products   5 Trials   435 News 


«123456»
  • ||||||||||  aldafermin (NGM282) / NGM Biopharmaceuticals
    [VIRTUAL] LIPID MANAGEMENT IN A 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALDAFERMIN (NGM282) () -  Oct 11, 2020 - Abstract #AASLD2020AASLD_1678;    
    ROS can safely manage the cholesterol increase seen in NASH patients treated with aldafermin, producing an overall favorable lipid, lipoprotein and ASCVD profile. Given the recent revisions in society guidelines, lipid management goals based on the ASCVD risk score, rather than a particular LDL-C target value, should be implemented for future studies.
  • ||||||||||  NGM621 Intravitreal / NGM Biopharma
    Trial completion, Enrollment change, Trial completion date:  Study of NGM621 in Participants With Geographic Atrophy (clinicaltrials.gov) -  Sep 30, 2020   
    P1,  N=15, Completed, 
    These results are consistent with our previous 12-week studies, demonstrating durable response and accumulation of histological benefit over time. Active, not recruiting --> Completed | N=24 --> 15 | Trial completion date: Dec 2020 --> May 2020
  • ||||||||||  aldafermin (NGM282) / NGM Biopharma
    Trial completion, Trial completion date, Trial primary completion date:  Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) (clinicaltrials.gov) -  Sep 10, 2020   
    P2,  N=254, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Sep 2019 --> Jan 2020 | Trial primary completion date: Sep 2019 --> Dec 2019
  • ||||||||||  aldafermin (NGM282) / NGM Biopharmaceuticals
    Journal:  Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis. (Pubmed Central) -  Jun 19, 2020   
    Administration of NGM282 to healthy volunteers for seven days resulted in a 26% increase in HDL-C levels compared with placebo. These findings outline a previously unrecognized role for FGF19 in the homeostatic control of cholesterol and may have direct impact on the clinical development of FGF19 analogues.
  • ||||||||||  PF-05231023 / Pfizer, LY2405319 / Eli Lilly, aldafermin (NGM282) / NGM Biopharmaceuticals
    Clinical, Journal:  Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application. (Pubmed Central) -  Jun 10, 2020   
    Clinical trials with FGF-based drugs report beneficial effects in lipid and bile acid metabolism, with clinical improvements in dyslipidemia, steatosis, weight loss, and liver damage. In contrast, glucose-lowering effects, as observed in preclinical models, are currently lacking.
  • ||||||||||  aldafermin (NGM282) / NGM Biopharmaceuticals
    [VIRTUAL] Correlation of serum bile acids and pruritus with aldafermin (NGM282) therapy in patients with primary sclerosing cholangitis (Poster Area) -  May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1058;    
    Given that liver fibrosis progression and HCC growth are associated with matrix stiffness and cross-linking of collagens, these results may support an anti-tumor activity, in addition to the anti-fibrotic activity, of aldafermin in chronic liver disease. Reductions in serum GCA and GCDCA correlated with reductions in 5D-itch score in PSC patients treated with aldafermin, suggesting that these BA species may serve as markers of pruritus response to aldafermin treatment.
  • ||||||||||  aldafermin (NGM282) / NGM Biopharma
    Trial initiation date:  Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) (clinicaltrials.gov) -  Apr 28, 2020   
    P2b,  N=150, Recruiting, 
    Aldafermin 1mg maintained a durable response for 24 weeks with a favorable tolerability and safety profile. Initiation date: Dec 2019 --> Mar 2020
  • ||||||||||  aldafermin (NGM282) / NGM Biopharma
    Trial completion, Trial completion date:  Study of Aldafermin (NGM282) in Participants With Impaired Renal Function (clinicaltrials.gov) -  Apr 27, 2020   
    P1,  N=48, Completed, 
    Initiation date: Dec 2019 --> Mar 2020 Recruiting --> Completed | Trial completion date: Jun 2020 --> Dec 2019
  • ||||||||||  NGM395 / NGM Biopharma
    Enrollment open:  Study of NGM395 in Adult Participants (clinicaltrials.gov) -  Mar 23, 2020   
    P1,  N=80, Recruiting, 
    Recruiting --> Completed | Trial completion date: Jun 2020 --> Dec 2019 Not yet recruiting --> Recruiting
  • ||||||||||  NGM621 Intravitreal / NGM Biopharma
    Enrollment closed:  Study of NGM621 in Participants With Geographic Atrophy (clinicaltrials.gov) -  Mar 4, 2020   
    P1,  N=24, Active, not recruiting, 
    NGM621 is currently being evaluated in a Phase 1 clinical trial for safety and tolerability in patients with GA. Recruiting --> Active, not recruiting